The Michigan Medicine Department of Radiation Oncology is a worldwide leader in cancer treatment and research. The novel research studies and clinical trials conducted by our faculty drives discovery and advances our cancer treatment delivery and effectiveness.
To learn more about the studies in Radiation Oncology listed below, please email Jody Sharp or phone 734-615-4909.
Questions about cancer treatment at Michigan Medicine can also be addressed at the Comprehensive Cancer Center AnswerLine: (800) 865-1125.
List of Trials
RTOG 1119: Phase II Randomized study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in combination with concurrent Lapatinib in patients with Brain metastasis from HER-2 positive breast cancer
NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
UMCC 2012.006: Phase II Study of High Dose Radiotherapy and Concurrent Temozolomide Using Biologically-Based Target Volume Definition in Patients with Newly Diagnosed Glioblastoma
RTOG 1071 / ALLIANCE N0577: Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma (Alliance N0577)
NRG-BN001: Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Head & Neck
UMCC 2013.062: Randomized Phase II study of DCE-MRI-based dose escalation for poor-prognosis head and neck cancer
UMCC 2015.073: Benefits of MPACT in Locally Advanced Head and Neck Cancer Patients Undergoing Chemoradiotherapy
NRG-HN001: Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
UMCC 2014.111: The IDEA Study (Individualized Decisions for Endocrine therapy Alone)
UMCC 2014.151: Pilot Study of Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure Following Breast Radiotherapy
UMCC 2015.147: Uncovering Mechanisms Responsible for Shoulder Morbidity Following Radiotherapy
UMCC 2015.035: A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients with Locally Advanced Non-Small Cell Lung Cancer (R-DART)
UMCC 2015.006: Early Imaging Biomarkers to Predict Radiation-Induced Cardiopulmonary Toxicity in Patients with Thoracic Malignancies
UMCC 2015.146: Functional Outcomes for Stereotactic Body Radiotherapy of Lung Lesions in High Risk Patients
UMCC 2017.001: A Phase II Randomized Trial Comparing Stereotactic Body Radiation Therapy to Microwave Ablation for the Treatment of Localized Hepatocellular Carcinoma
UMCC 2015.039: A Pilot Study of Individualized Adaptive Radiation Therapy for Hepatocellular Carcinoma
UMCC 2003.081: Assessment of Liver Function in Patients Undergoing Hepatic Irradiation
UMCC 2006.067: A Pilot Study of Radiation Toxicity Using MRI-Based Perfusion.
UMCC 2013.094: A Dose Escalation Trial of the Wee1 Inhibitor MK1775, in Combination with Gemcitabine (+Radiation) for Patients with Unresectable Adenocarcinoma of the Pancreas
HUM00085016: A Study of Circulating Tumor Cells and Exosomes in Patients Treated with Chemoradiation for Adenocarcinoma of the Pancreas
UMCC 2014.142: Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy
UMCC 2015.182: Androgen Deprivation Therapy with or without Radium-223 dichloride in Patients with Newly Diagnosed Metastatic Prostate Cancer with Bone Metastases: HCRN GU13-170
UMCC 2016.072: ARN-509 + Abiraterone acetate + Leuprolide with Stereotactic, Ultra-Hypofractionated Radiation (AASUR) in Very High Risk Prostate Cancer: A Single Arm, Phase II Study
UMCC 2016.106: A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for High Risk Prostate Cancer
RTOG 0924: Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
NRG-GU002: Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
New NRG Study Coming Soon!
UMCC 2012.113: Optimization of MRI for Radiation Therapy
Kim 0005: Prospective Registry Trial of Patients with Focal Hypofractionated Image Guided Radiation Therapy For Brain Metastases at the VA Ann Arbor Healthcare System
Kim 0004: A Pilot Study of Circulating Tumor Cells in Patients Undergoing Definitive Radiation Therapy at the Veterans Affairs Ann Arbor Healthcare System
RTOG 0924/Shumway 0001: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
UMCC 2013.062/Mierzwa 0001: Randomized Phase II Study of DCE-MRI Based Dose Escalation for Poor-Prognosis Head and Neck Cancer
Mierzwa 0002: Prospective Registry Trial of Patients Treated with Stereotactic Body Radiotherapy for Recurrent or Second Primary Head and Neck Cancer at the VA Ann Arbor Healthcare System
Mierzwa 0003: Mitigation of Radiation Pneumonitis & Fibrosis (ACE inhibitor trial)
Mierzwa 0004: Observational Phase 2 trial of mid-treatment and early post-treatment PET-CT during definitive chemoradiation for Squamous cell carcinoma of the oropharynx at the AAVA (PET study)
UMCC 2015.035/Mierzwa 0005: A Pilot Study of Response-Driven Adaptive Radiation Therapy For Patients with Locally Advanced NSCLCa